Business
Crescita Reports Q4 and Fiscal 2024 Results
Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or th...
About this update from Crescita Therapeutics, Inc.
[{"type":"text","content":"Crescita Reports Q4 and Fiscal 2024 Results\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n.bwalignr { text-align: right; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwdoublebottom { border-bottom: double black 2.25pt }\n.bwlistdecimal { list-style-type: decimal }\n.bwlistdisc { list-style-type: disc }\n.bwlistsquare { list-style-type: square }\n.bwnowrap { white-space: nowrap }\n.bwpadb3 { padding-bottom: 4px }\n.bwpadb4 { padding-bottom: 5px }\n.bwpadl0 { padding-left: 0px }\n.bwpadr0 { padding-right: 0px }\n.bwrowaltcolor1 { background-color: #d3d3d3 }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwvertalignb { vertical-align: bottom }\n.bwvertalignt { vertical-align: top }\n.bwwidth1 { width: 1% }\n.bwwidth10 { width: 10% }\n.bwwidth100 { width: 100% }\n.bwwidth2 { width: 2% }\n.bwwidth59 { width: 59% }\n.bwwidth6 { width: 6% }\n.bwwidth66 { width: 66% }\n.bwwidth7 { width: 7% }\n.bwwidth8 { width: 8% }\n.bwwidth9 { width: 9% }\n \n\n\n\n Crescita Therapeutics Inc. (\n \n TSX: CTX\n \n and\n \n OTC US: CRRTF\n \n ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2024 (“Q4-2024” and “F2024”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.\n \n\n\n Financial Highlights\n \n\n\n\n Q4-2024 vs. Q4-2023\n \n\n\n\n Revenue was $6,902 compared to $4,725, up $2,177;\n \n\n Gross profit was $2,995 compared to $3,060, down $65;\n \n\n Operating expenses were $3,263 compared to $3,173, up $90;\n \n\n Net loss was $(162) compared to $(150), up $12;\n \n\n Adjusted EBITDA\n \n\n 1\n \n\n was $151 compared to $245, down $94.\n \n\n\n\n F2024 vs. F2023\n \n\n\n\n Revenue was $19,580 compared to $17,522, up $2,058;\n \n\n Gross profit was $9,608 compared to $10,364, down $756;\n \n\n Operating expenses were $12,823 compared to $12,320, up $503;\n \n\n Net loss w...